

Online supplement to: Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States. *The Journal of Rheumatology*. doi:10.3899/jrheum.191187.

**ONLINE SUPPLEMENTARY MATERIAL**

**Supplemental material for manuscript: Health Care Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States**

Irene B. Murimi, Dora H. Lin, Hong Kan, Jonathan Tierce, Xia Wang, Henk Nab, Barnabas Desta, G. Caleb Alexander, Edward R. Hammond

**Supplementary Table 1. Algorithm for assigning patients to categories for SLE severity**

<b>Disease Categorization</b>		
<b>Mild Disease</b>	<b>Moderate Disease</b>	<b>Severe Disease</b>
Did not meet moderate or severe SLE criteria <sup>a</sup>	<p>No filled prescriptions for cyclophosphamide/rituximab/oral corticosteroid with <math>\geq 60</math> mg/d of prednisone-equivalent dosage</p> <p>No claims with a diagnosis of a severe condition; AND</p> <p>Met one or both of following any time during follow-up:</p> <ul style="list-style-type: none"> <li>• <math>\geq 1</math> non-laboratory claim with a diagnosis of a condition listed as moderate,<sup>b</sup> in which the diagnosis occurs in any position on the claim;</li> <li>OR</li> <li>• Filled prescription for an oral corticosteroid with a prednisone-equivalent dosage of <math>\geq 7.5</math> mg/d and <math>&lt; 60</math> mg/d or for an immunosuppressive agent (other than cyclophosphamide)</li> </ul>	<p><math>\geq 1</math> filled prescription for cyclophosphamide or rituximab or oral corticosteroid with a prednisone-equivalent dosage of <math>\geq 60</math> mg/d;</p> <p>OR</p> <p>Had <math>\geq 1</math> non-laboratory claim with a diagnosis listed as severe,<sup>c</sup> in which the diagnosis occurs in any position on the claim</p>

<sup>a</sup>Patients who died and had  $< 1$  month (30 days) of enrollment for each year of study were classified as having died with short enrollment rather than being assigned an SLE disease severity level.

<sup>b</sup>Moderate conditions: acute pancreatitis, chorioretinitis, demyelinating syndrome/acute inflammatory demyelinating polyradiculoneuropathy,

episcleritis/scleritis, hemolytic anemia, hepatitis (non-viral), ischemic necrosis of bone, nephritis, renal impairment other than nephritis or end stage renal disease, lupus enteritis/colitis, mononeuropathy/polyneuropathy, myelopathy, myocarditis, pericarditis, pleurisy/pleural effusion, pseudotumor cerebri, seizure, uveitis vasculitis (excluding aortitis)

°Severe conditions: Acute confusional state/psychosis, aortitis, arterial/venous thrombosis, aseptic meningitis, cardiac tamponade, cranial neuropathy, intestinal pseudo-obstruction, end stage renal disease, optic neuritis, pulmonary hemorrhage, stroke/TIA